CA3068917A1 - Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes - Google Patents

Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes Download PDF

Info

Publication number
CA3068917A1
CA3068917A1 CA3068917A CA3068917A CA3068917A1 CA 3068917 A1 CA3068917 A1 CA 3068917A1 CA 3068917 A CA3068917 A CA 3068917A CA 3068917 A CA3068917 A CA 3068917A CA 3068917 A1 CA3068917 A1 CA 3068917A1
Authority
CA
Canada
Prior art keywords
mineral
interferon
combinations
composition
ribonucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068917A
Other languages
English (en)
French (fr)
Inventor
William L. Murphy
Andrew Salim KHALIL
Xiaohua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CA3068917A1 publication Critical patent/CA3068917A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3068917A 2017-07-05 2018-07-05 Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes Pending CA3068917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528566P 2017-07-05 2017-07-05
US62/528,566 2017-07-05
PCT/US2018/040928 WO2019010310A1 (en) 2017-07-05 2018-07-05 MINERAL-COATED MICROPARTICLES FOR CO-ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES AND NUCLEIC ACIDS TO IMPROVE GENE DELIVERY RESULTS

Publications (1)

Publication Number Publication Date
CA3068917A1 true CA3068917A1 (en) 2019-01-10

Family

ID=64950341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068917A Pending CA3068917A1 (en) 2017-07-05 2018-07-05 Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes

Country Status (6)

Country Link
US (2) US11065208B2 (https=)
EP (1) EP3648750A4 (https=)
JP (1) JP2020526515A (https=)
CN (1) CN111050757A (https=)
CA (1) CA3068917A1 (https=)
WO (1) WO2019010310A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187344A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
WO2022031594A1 (en) * 2020-08-06 2022-02-10 Dianomi Therapeutics, Inc. Compositions and methods for vaccine delivery
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
CN115227676B (zh) * 2022-07-04 2023-10-24 浙江大学 一种缓释mRNA的矿物包被微粒材料及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317807A1 (en) * 2007-06-22 2008-12-25 The University Of Hong Kong Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9862926B2 (en) * 2011-06-27 2018-01-09 Cellscript, Llc. Inhibition of innate immune response
CN104508131B (zh) 2012-05-21 2018-11-23 加利福尼亚大学董事会 通过合成的自我复制的RNA形成人iPS细胞
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection
EP3046933B1 (en) * 2013-09-18 2019-02-27 BCN Peptides, S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes

Also Published As

Publication number Publication date
US20200170958A1 (en) 2020-06-04
EP3648750A4 (en) 2021-05-26
US11065208B2 (en) 2021-07-20
CN111050757A (zh) 2020-04-21
EP3648750A1 (en) 2020-05-13
JP2020526515A (ja) 2020-08-31
US11779542B2 (en) 2023-10-10
US20210353549A1 (en) 2021-11-18
WO2019010310A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US11779542B2 (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
AU2020203367A1 (en) Compositions and methods for treating lung diseases and lung injury
EP2791336B1 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
US20250213496A1 (en) Lipid nanoparticles and preparation methods and use thereof
Yamashita et al. A novel bubble liposome and ultrasound-mediated gene transfer to ocular surface: RC-1 cells in vitro and conjunctiva in vivo
US20260041786A1 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
WO2023036345A1 (zh) 一种雾化吸入的载药纳米颗粒以及用于治疗肺纤维化的siRNA序列组及其设计方法
Lei et al. Exosome-like vesicles encapsulated with specific microRNAs accelerate burn wound healing and ameliorate scarring
EP2391717A1 (en) Treatment of radiation-induced fibrosis
US20190358344A1 (en) Mineral coated microparticles for sustained delivery of steroids
US11628227B2 (en) Mineral coated microparticles for gene delivery in chronic wound therapy
JP2010511692A (ja) イオントフォレシスを通じての核酸の強化された網膜送達
Gu et al. Developing Biomaterial‐Based mRNA Delivery System for Lung Disease Treatment
HK40020489A (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
EP4577193A1 (en) Compositions and methods for the delivery of active agents including nucleic acids
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
WO2026057679A1 (en) Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)
HK40014557A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
CN121622617A (zh) 硫酸软骨素修饰二氢杨梅素固体脂质纳米粒
Westra et al. INDUCTION OF FIBROTIC MARKERS IN ANIN VITROMODEL OF LIVER FIBROSIS: 836
CN102188711B (zh) 包载药物类脂微粒的制备方法
CN116196326A (zh) miRNA剂型的骨关节炎药物制剂及其制备方法
CN120754262A (zh) 一种核酸递送载体及其制备方法和应用